Of the total 2451 patients receiving rivaroxaban or edoxaban for VTE or AF during the study period, 361 patients receiving these two FXa inhibitors for concomitant presence of other respiratory diseases were enrolled. The gene discussed is F10; the disease is respiratory system disorder.